v3.26.1
Segments - Schedule of Reportable Segment Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Stock-based compensation expense $ 2,191 $ 1,208
Interest income, net (1,696) (1,125)
Net loss 13,192 10,340
Segment [Member]    
Segment Reporting Information [Line Items]    
Chronic cough in IPF clinical trial expense 1,688 2,882
Refractory chronic cough clinical trial expense 1,078 818
Other clinical trials and studies [1] 1,553 48
Clinical trial material 1,299 234
Other clinical development expenses [2] 1,523 1,418
Employee compensation (excluding stock compensation expense) 3,159 2,958
Stock-based compensation expense 2,191 1,208
Other segment items [3] 2,397 1,899
Interest income, net (1,696) (1,125)
Net loss $ 13,192 $ 10,340
[1] Includes expense related to the Company’s Phase 1 NDA supportive studies
[2] Includes expense related to general research and development activities, regulatory, medical affairs, and quality assurance.
[3] Includes general administrative expense, other (expense) income, net and income tax benefit.